hide message

Welcome to the Resource Centre

We make it our mission to work with advocates in civil society, business and government to address inequalities of power, seek remedy for abuse, and ensure protection of people and planet.

Both companies and impacted communities thank us for the resources and support we provide.

This is only possible because of your support. Please make a donation today.

Thank you,
Phil Bloomer, Executive Director

Donate now hide message

You are being redirected to the story the piece of content is found in so you can read it in context. Please click the following link if you are not automatically redirected within a couple seconds:
en/novartis-responds-to-concerns-raised-about-the-social-environmental-impacts-of-its-business-practices#c171611

Response by Novartis

Author: Novartis, Published on: 16 April 2018

At Novartis, corporate responsibility (CR) is central to how we run our business. Our CR strategy supports our company mission to discover new ways to improve and extend people’s lives and our vision to be a trusted leader in changing the practice of medicine. We focus our CR work in two key areas: expanding access to healthcare and doing business responsibly. 

To achieve our mission, we have a responsibility to use our expertise and skills to address the needs of underserved populations. We work to improve the affordability and availability of our medicines by pioneering sustainable and scalable access models. And we seek effective partnerships to help deliver treatments and quality care to as many people as possible. Read more about our access-to-healthcare programs on our website...

As a responsible company, we are committed to conducting our business in a manner that respects the rights and dignity of all people. Our full Modern Slavery Statement is available on our website. We are also fully committed to a cleaner environment for the benefit of our patients, our investors and our communities. More details on our approach to environmental sustainability are available on our website...

Read the full post here

This is a response from the following companies: Novartis